For 2024 publications go here.

MARCH

Tang K, Zhou L, Tian X, Fang SY, Vandenbulcke E, Du A, Shen J, Cao H, Zhou J, Chen K, Kim HR, Luo Z, Xin S, Lin SH, Park D, Yang L, Zhang Y, Suzuki K, Majety M, Ling X, Lam SZ, Chow RD, Ren P, Tao B, Li K, Codina A, Dai X, Shang X, Bai S, Nottoli T, Levchenko A, Booth CJ, Liu C, Fan R, Dong MB, Zhou X, Chen S. Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering. Nat Biomed Eng. 2025 Mar 20.

Cannataro VL, Bracci PM, Taylor JW, McCoy L, Rice T, Hansen HM, Heffernan AE, Wiemels J, Wiencke J, Wrensch M, Claus EB. Glioma mutational signatures associated with haloalkane exposure are enriched in firefighters. Cancer. 2025 Mar 15;131(6):e35732.

Herbst RS, John T, Grohé C, Goldman JW, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Dómine M, Ahn MJ, Kowalski DM, Pérol M, Sriuranpong V, Özgüroğlu M, Bhetariya P, Markovets A, Rukazenkov Y, Muldoon C, Robichaux J, Hartmaier R, Tsuboi M, Wu YL. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med. 2025 Mar 17.

Kuhn TN, Engelhardt WD, Kahl VH, Alkukhun A, Gross M, Iseke S, Onofrey J, Covey A, Camacho JC, Kawaguchi Y, Hasegawa K, Odisio BC, Vauthey JN, Antoch G, Chapiro J, Madoff DC. Artificial Intelligence-Driven Patient Selection for Preoperative Portal Vein Embolization for Patients with Colorectal Cancer Liver Metastases. J Vasc Interv Radiol. 2025 Mar;36(3):477-488.

Kimchi G, Lamsam L, Gu B, Mendel E, Harel R, Knoller N, Cohen ZR, Ungar L, Zibly Z. Minimally Invasive Anterolateral Cervical Cordotomy for Intractable Cancer Pain Using Microtubular Retractors: A Single Institution Case Series. Oper Neurosurg (Hagerstown). 2025 Mar 1;28(3):386-390.

Cannataro VL, Bracci PM, Taylor JW, McCoy L, Rice T, Hansen HM, Heffernan AE, Wiemels J, Wiencke J, Wrensch M, Claus EB. Glioma mutational signatures associated with haloalkane exposure are enriched in firefighters. Cancer. 2025 Mar 15;131(6):e35732.

Norman KE, Buss MK, Lee KA, Escobar A, Thomas J, Berg J, Uwumugambi N, Dodge LE, Han HJ, Pilgrim C, Yeh JC. Impact of a Criteria-Based Inpatient Palliative Oncology Consultation Model on End-of-Life Outcomes. J Pain Symptom Manage. 2025 Mar;69(3):229-235.e1.

Clark CJ, Wang R, Wiemels JL, Metayer C, Deziel NC, Ma X. Perinatal exposure to ambient fine particle air pollution and risk of childhood ewing sarcoma in a population-based case-control study in California (1988-2015). Environ Health. 2025 Mar 7;24(1):6.

Hamid SA, Lee DH, Herrin J, Yu JB, Pollack CE, Dean LT, Gaddy JJ, Oladele CR, Feder SL, Canavan ME, Nunez-Smith M, Soulos PR, Gross CP. Mediators of Racial Inequities in Non-Small Cell Lung Cancer Care. Cancer Med. 2025 Mar;14(5):e70757.

Lopez de Rodas M, Villalba-Esparza M, Sanmamed MF, Chen L, Rimm DL, Schalper KA. Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach. Nat Rev Clin Oncol. 2025 Mar;22(3):163-181.

Nassar AH, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman RS, Johnson DB, Grynberg S, Shapira R, Kwan JM, Woodford R, Long GV, Haykal T, Dent S, Kojima Y, Yonemor K, Tandon A, Trevino A, Akhter N, Yang EH, Hui G, Drakaki A, El-Am E, Kozaily E, Al-Hader A, Bou Farhat E, Babu P, Mittra A, Li M, Jones N, Baena J, Juarez Herrera M, Foderaro S, Nana FA, Kim C, Sackstein P, Parikh K, Desai AP, Smith C, Cortellini A, Pinato DJ, Korolewicz J, Lopetegui-Lia N, Funchain P, Choudhary A, Asnani A, Navani V, Meyers D, Stukalin I, Ocejo Gallegos JA, Trent J, Nusrat S, Malvar C, McKay RR, Neilan TG, Choueiri TK, Naqash AR. Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study. J Immunother Cancer. 2025 Mar 3;13(3):e009364.

Belitzky E, Ravani Carvalho LV, Taylor M, Ortiz CN, Baum L, Fiellin DA, Lustberg MB. Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy. Cancer Med. 2025 Mar;14(5):e70586.

Gaspar E, Yi I, Bar N. Once weekly bortezomib decreases rates of peripheral neuropathy without diminishing efficacy as compared to twice weekly bortezomib in combination with lenalidomide, dexamethasone and daratumumab, a single center retrospective analysis. Leuk Lymphoma. 2025 Mar 10:1-4.

Herbst RS, John T, Grohé C, Goldman JW, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Dómine M, Ahn MJ, Kowalski DM, Pérol M, Sriuranpong V, Özgüroğlu M, Bhetariya P, Markovets A, Rukazenkov Y, Muldoon C, Robichaux J, Hartmaier R, Tsuboi M, Wu YL. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med. 2025 Mar 17.

FEBRUARY

Braun DA, Moranzoni G, Chea V, McGregor BA, Blass E, Tu CR, Vanasse AP, Forman C, Forman J, Afeyan AB, Schindler NR, Liu Y, Li S, Southard J, Chang SL, Hirsch MS, LeBoeuf NR, Olive O, Mehndiratta A, Greenslade H, Shetty K, Klaeger S, Sarkizova S, Pedersen CB, Mossanen M, Carulli I, Tarren A, Duke-Cohan J, Howard AA, Iorgulescu JB, Shim B, Simon JM, Signoretti S, Aster JC, Elagina L, Carr SA, Leshchiner I, Getz G, Gabriel S, Hacohen N, Olsen LR, Oliveira G, Neuberg DS, Livak KJ, Shukla SA, Fritsch EF, Wu CJ, Keskin DB, Ott PA, Choueiri TK. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature. 2025 Feb 5.

Turan V, Bedoschi G, Lee DY, Barbosa CP, de Oliveira R, Sacinti KG, Sonmezer M, Lambertini M, Massarotti C, Schaub A, Wang E, Gayete-Lafuente S, Dunlop C, Anderson RA, Bang H, Oktay KH. Trends and Regional Differences for Fertility Preservation Procedures in Women With Breast Cancer. Clin Breast Cancer. 2025 Feb;25(2):108-116.e1.

Turocy T, Crawford JM. Bacterial small molecule metabolites implicated in gastrointestinal cancer development. Nat Rev Microbiol. 2025 Feb;23(2):106-121.

Experiences of Simulated Phone Death Notification. Murtha TD, Johnson RR, Ellman MS, Martin AS, Morrison LJ, Talwalkar JS.Clin Teach. 2025 Feb;22(1):e13846.

Prostate cancer in people with HIV. Sigel K, Yu R, Chiao E, Deshmukh A, Leapman MS. Curr Opin Infect Dis. 2025 Feb 1;38(1):10-17.

Wang M, Cai G, Gilani SM. TRPS1 expression in cytologic specimens of salivary duct carcinoma and other salivary gland tumors. Ann Diagn Pathol. 2025 Feb;74:152406.

Marczyk M, Kahn A, Silber A, Rosenblit M, Digiovanna MP, Lustberg M, Pusztai L. Trends in breast cancer-specific death by clinical stage at diagnoses between 2000 and 2017. J Natl Cancer Inst. 2025 Feb 1;117(2):287-295.

Cecchini M, Pilat MJ, Uboha N, Azad NS, Cho M, Davis EJ, Ahnert JR, Tinoco G, Shapiro GI, Khagi S, Powers B, Spencer K, Groisberg R, Drappatz J, Chen L, Das B, Bao X, Li J, Narayan A, Vu D, Patel A, Niger M, Doroshow D, Durecki D, Boerner SA, Bindra R, Ivy P, Shyr D, Shyr Y, LoRusso PM. Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial. Cancer. 2025 Feb 15;131(4):e35755.

Robles JT, Stiegler AL, Boggon TJ, Turk BE. Cancer hotspot mutations rewire ERK2 specificity by selective exclusion of docking interactions. J Biol Chem. 2025 Feb 25:108348.

Ko CJ. Healing while healing: Navigating breast cancer as a doctor. J Am Acad Dermatol. 2025 Feb 21:S0190-9622(25)00326-3.

Cecchini M, Pilat MJ, Uboha N, Azad NS, Cho M, Davis EJ, Ahnert JR, Tinoco G, Shapiro GI, Khagi S, Powers B, Spencer K, Groisberg R, Drappatz J, Chen L, Das B, Bao X, Li J, Narayan A, Vu D, Patel A, Niger M, Doroshow D, Durecki D, Boerner SA, Bindra R, Ivy P, Shyr D, Shyr Y, LoRusso PM. Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial. Cancer. 2025 Feb 15;131(4):e35755.

Turan V, Bedoschi G, Lee DY, Barbosa CP, de Oliveira R, Sacinti KG, Sonmezer M, Lambertini M, Massarotti C, Schaub A, Wang E, Gayete-Lafuente S, Dunlop C, Anderson RA, Bang H, Oktay KH. Trends and Regional Differences for Fertility Preservation Procedures in Women With Breast Cancer. Clin Breast Cancer. 2025 Feb;25(2):108-116.e1.

Exarchos A, Bourla AB, Kaur M, Schulze K, Maund S, Cao Y, Zhao Y, Williams EH, Gaffey SC, Zuniga R, Lakhanpal S, Antic V, Doral M, Sy J, Meropol NJ, Chiang AC. Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform. Contemp Clin Trials Commun. 2025 Feb 4;44:101446.

JANUARY

Butensky SD, Kerekes D, Bakkila BF, Billingsley KG, Ahuja N, Johnson CH, Khan SA. Quality of gastrointestinal surgical oncology care according to insurance status. J Gastrointest Surg. 2025 Mar;29(3):101961. Epub 2025 Jan 10.

Canavan ME, Westvold S, Csik V, Franks J, Rocque G, Gross CP, Adelson KB. The association between clinical trial participation, drug costs, and performance in the Oncology Care Model (OCM). J Natl Cancer Inst. 2025 Jan 22:djaf008.

Sundaresan VM, Smani S, Rajwa P, Renzulli J, Sprenkle PC, Kim IY, Leapman MS. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urol Oncol. 2025 Jan;43(1):41-48.

Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Li H, Kim JH, Zhao H, Li CL, Madoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS, Llovet JM; LEAP investigators. Lenvatinib plus pembrolizumab plus transarterial chemoembolisation (TACE) versus dual placebo plus TACE for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a randomised, double-blind, phase 3 study. Lancet 2025 Jan 18;405(10474):203-215.

Ng M, Cerezo-Wallis D, Ng LG, Hidalgo A. Adaptations of neutrophils in cancer. Immunity. 2025 Jan 14;58(1):40-58.

Ayoade OF, Canavan ME, De Santis WP, Zhan PL, Boffa DJ. Surgical and endoscopic management of clinical T1b esophageal cancer. J Thorac Cardiovasc Surg. 2025 Jan;169(1):279-288.e5.

Harrington K, Kitano S, Gambardella V, Parkes EE, Moreno I, Alonso G, Doi T, Berz D, Gutierrez ME, Fernandez N, Schmohl M, Barrueco J, LoRusso P. Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors. Future Oncol. 2025 Jan;21(2):195-200.

Lu BY, Lucca LE, Lewis W, Wang J, Nogueira CV, Heer S, Rayon-Estrada V, Axisa PP, Reeves SM, Buitrago-Pocasangre NC, Pham GH, Kojima ML, Wei W, Aizenbud L, Bacchiocchi A, Zhang L, Walewski JJ, Chiang V, Olino K, Clune J, Halaban R, Kluger Y, Coyle AJ, Kisielow J, Obermair FJ, Kluger HM, Hafler DA. Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanoma. Nat Immunol. 2025 Jan;26(1):82-91.

Khubchandani JA, Suttiratana SC, Washington R, White-Bracey D, Kc M, Silber A, Fayanju OM, Butler PD, Menon A, Greenup RA. Living Flat: Stories from Women of Color After Mastectomy. Ann Surg Oncol. 2025 Jan;32(1):104-114.

Junejo MH, Oyebanji OI, Wang B, Cappello C, Wait B, Farrow E, Nathan M, Bowring J, Cuming T. Early detection of anal squamous cell carcinoma with the use of high-resolution anoscopy. Clin Exp Dermatol. 2025 Jan 27;50(2):395-398.

Are C, Schissel M, Murthy S. Series on The Lancet Oncology Commission on Global Cancer Surgery-Action 1: Clinical Care and Access to Cancer Surgery. Ann Surg Oncol. 2025 Jan;32(1):42-46.

Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L. Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history. Breast Cancer Res Treat. 2025 Jan;209(1):21-26.

Wang Y, Zhang Y, Li W, Salovska B, Zhang J, Li T, Li H, Liu Y, Kaczmarek LK, Pusztai L, Klein DE. GABAA receptor π forms channels that stimulate ERK through a G-protein-dependent pathway. Mol Cell. 2025 Jan 2;85(1):166-176.e5.

Jiang Z, Bi F, Ge Z, Mansolf M, Hartwich TMP, Kolesnyk V, Yang K, Park W, Kim D, Grechukhina O, Hui P, Kim SW, Yang-Hartwich Y. SORL1-Mediated EGFR and FGFR4 Regulation Enhances Chemoresistance in Ovarian Cancer. Cancers (Basel). 2025 Jan 13;17(2):244.

AACR Cancer Progress Report 2024 Steering Committee. New Approvals Advancing Blood Cancer Medicine. Blood Cancer Discov. 2025 Jan 8;6(1):5-9.

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer with 34+ contributing authors including DiGiovanna, M. of Yale. 15 Jan 2025 N Engl J Med 2025;392:249-257

Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies. Bewersdorf JP, Mi X, Lu B, Kuykendall A, Sallman D, Patel M, Stevens D, Philipovskiy A, Sutamtewagul G, Masarova L, Keiffer G, Verma A, Bhagwat N, Wang M, Moore A, Rager J, Heiser D, Ro S, Hong WJ, Abdel-Wahab O, Stein EM. Leukemia. 2025 Jan 24.

Comparison of incident breast cancer cases in the largest national US tumor registries. Plichta JK, Thomas SM, Chanenchuk TC, Chan K, Hyslop T, Hwang ES, Greenup RA. Cancer. 2025 Jan 1;131(1):e35525. Online ahead of print

Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Sundaresan VM, Smani S, Rajwa P, Renzulli J, Sprenkle PC, Kim IY, Leapman MS Urol Oncol. 2025 Jan;43(1):41-48. doi: 10.1016/j.urolonc.2024.06.003.

Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. #10; Click to follow link.">Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. Yu EY, Rumble RB, Agarwal N, Cheng HH, Eggener SE, Bitting RL, Beltran H, Giri VN, Spratt D, Mahal B, Lu K, Crispino T, Trabulsi EJ. J Clin Oncol. 2025 Jan 9:JCO2402608.

Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Jammihal T, Saliby RM, Labaki C, Soulati H, Gallegos J, Peris A, McCurry D, Yu C, Shah V, Poduval D, El Zarif T, El Ahmar N, Laimon YN, Eid M, Sheshdeh AB, Krajewski KM, Büttner FA, Schwab M, Heng D, Casellas RC, Rai K, Zacharias Millward NM, Msaouel P, Karam J, Signoretti S, Van Allen E, Choueiri TK, Braun DA, Shukla SA. Nat Cancer. 2025 Jan 9.

DNA methylation in mammalian development and disease. Smith ZD, Hetzel S, Meissner A. Nat Rev Genet. 2025 Jan;26(1):7-30.

Varying the intensity of cystoscopic surveillance for high-risk non-muscle-invasive bladder cancer. Su ZT, Florissi IS, Mahon KM, Li T, Rezaee ME, Singla N, Patel SH, Townsend JP, Kates MR. BJU Int. 2025 Jan;135(1):148-155.

AAHPM Assessment Workgroup: Hospice and Palliative Medicine Fellowship Assessment Needs and Directions. Ketterer B, Dingfield L, Stowers KH, Morrison K, Bailey A, Flint H, Buckholz G, Morrison LJ, Yang H, Berns S. J Pain Symptom Manage. 2024 Dec 19:S0885-3924(24)01210-7.

Tumor-Specific Antigen Delivery for T-cell Therapy via a pH-Sensitive Peptide Conjugate. Yurkevicz AM, Liu Y, Katz SG, Glazer PM. Mol Cancer Ther. 2025 Jan 2;24(1):105-117.

Sorafenib or anthracycline-based chemotherapy for progressive desmoid tumors. Costa PA, Arora A, Fernandez Y, Yi I, Bakkila B, Tan H, Barreto Coelho P, Campoverde L, Hardy N, Bialick S, Espejo Freire A, D'Amato GZ, Chang YC, Mesenger JP, Subhawong T, Haims A, Hurwitz M, Olino K, Turaga K, Deshpande H, Trent J. Cancer. 2025 Jan 1;131(1):e35647.